AFT Pharmaceuticals Limited

AFT

NZAFTE0001S4

Pharmaceuticals

End-of-day quote New Zealand S.E. Other stock markets 23:00:00 20/06/2024 BST			5-day change	1st Jan Change
2.85 ^NZD	-6.25%		-9.81%	-18.57%

06-04	New Zealand Shares Flat; Scott Technology Adds Meat Cutter to Brand Portfolio	MT
06-03	AFT Pharmaceuticals Partners with Alexso to Bring Pain Relief Drug to US Market	MT

AFT Pharmaceuticals Limited Announces Ordinary Dividend for the Twelve Months Ended Mach 31, 2024, Payable on July 4, 2024

May 22, 2024 at 10:32 pm

AFT Pharmaceuticals Limited announced ordinary dividend of NZD 0.01600000 per share for the twelve months ended Mach 31, 2024. Ex Date is June 19, 2024; Record Date is June 20, 2024; Payment Date is July 4, 2024.

Latest news about AFT Pharmaceuticals Limited

New Zealand Shares Flat; Scott Technology Adds Meat Cutter to Brand Portfolio	06-04	MT
AFT Pharmaceuticals Partners with Alexso to Bring Pain Relief Drug to US Market	06-03	MT
AFT Pharmaceuticals Limited to Launch Maxigesic Rapid in the United States	06-03	CI
AFT Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-23	CI
Transcript : AFT Pharmaceuticals Limited, 2024 Earnings Call, May 23, 2024	05-22
AFT Pharmaceuticals' Net Profit Climbs 46% in Fiscal 2024; Dividend Declared	05-22	MT
AFT Pharmaceuticals Limited Announces Ordinary Dividend for the Twelve Months Ended Mach 31, 2024, Payable on July 4, 2024	05-22	CI
AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV	05-01	MT
AFT Pharmaceuticals Limited Licenses Maxigesic IV in Brazil	04-30	CI
New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment	04-24	MT
AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment	04-24	MT
AFT Pharmaceuticals Limited, Massey Ventures, Gilles Mcindoe Research Institute to Develop Scar Treatment	04-23	CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down	03-04	MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals	03-04	MT
Aft Expands Its Co-Operation with Hikma Pharmaceuticals	03-03	CI
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance	02-16	MT
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024	02-16	MT
AFT Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024	02-15	CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%	02-07	MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US	02-06	MT
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication	01-18	MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus	01-18	CI
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate	12-22	MT
AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals	12-21	CI
France keeps 2024 bond issuance steady at 285 bln euros	12-13	RE

Chart AFT Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for AFT Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.85 NZD

Average target price

3.75 NZD

Spread / Average Target

+31.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AFT PHARMACEUTICALS LIMITED	-18.57%	183M
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals